默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可

美港电讯11-14

【默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可】金十数据11月14日讯，默沙东与礼新医药科技有限公司11月14日宣布，默沙东已协议获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。根据协议条款，礼新医药已授权默沙东LM-299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483879631?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-14 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483879631","market":"us","top_or_hot":-1,"title":"默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可","media":"美港电讯","content":"<html><body><p>【默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可】金十数据11月14日讯，默沙东与礼新医药科技有限公司11月14日宣布，默沙东已协议获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。根据协议条款，礼新医药已授权默沙东LM-299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。</p></body></html>","source":"live_meigang","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">美港电讯</strong><span class=\"h-time small\">2024-11-14 20:13</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>【默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可】金十数据11月14日讯，默沙东与礼新医药科技有限公司11月14日宣布，默沙东已协议获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。根据协议条款，礼新医药已授权默沙东LM-299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.ushknews.com/\">美港电讯</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989771016.USD","symbol_name":"东方汇理环球老龄化投资基金 A2 Acc","start_time":0,"source_url":"https://www.ushknews.com/","article_id":"2483879631","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483879631","pubTimestamp":1731586425,"sourceInfo":{"source_id":"live_meigang","name":"美港电讯"},"weMediaInfo":null,"summary":"【默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可】金十数据11月14日讯，默沙东与礼新医药科技有限公司11月14日宣布，默沙东已协议获得礼新医药新型在研PD-1/V","collect":0,"end_time":0,"defaultTopTitle":"ushknews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","PD":"PagerDuty, Inc.","LU0238689110.USD":"贝莱德环球动力股票基金","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4007":"制药","MRK":"默沙东","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK1161":"生物科技","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","BK4023":"应用软件","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999002224.SGD":"Allianz Global High Payout SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","09939":"开拓药业-B","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4559":"巴菲特持仓"},"translate_title":"Merck: Agreement to obtain the exclusive global license of Lixin Pharmaceutical's PD-1/VEGF bispecific antibody LM-299","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"MRK":1,"PD":1,"09939":1},"content_text":"【默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可】金十数据11月14日讯，默沙东与礼新医药科技有限公司11月14日宣布，默沙东已协议获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。根据协议条款，礼新医药已授权默沙东LM-299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483879631"}